The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed ...

The notes will be general unsecured, senior obligations of Ligand and will accrue interest payable semiannually in arrears on April 1 and October 1 of each year, beginning on April 1, 2026. The notes ...

USPTO Issues Patent No. US 12,343,315 B2 covering topical cannabinoid compositions for clear skin. TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “C ...

The leadership transition is part of the Board’s ongoing succession planning and aligns with the Company’s planned advancement into Phase 3 development of pemvidutide in metabolic ...

Research and development expenses for the second quarter of 2025 increased to $10.8 million from $6.4 million for the prior year period. The increase was primarily due to a $3.9 million increase in ...

Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over ...

The following videos, which include CEO interviews, are now available on the Company’s website at the bottom of the Welcome page: https://greenwichlifesciences.com/ The Company's recent prior events ...

Troy Cox, who served on Zymeworks’ Board since 2019, has stepped down.

Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren’s disease Novartis plans to present its data at an upcoming medical congress and submit ...

For the three months ended June 30, 2025, the Company reported a net loss of $16.3 million, compared to a net loss of $9.5 million for the same period in 2024. For the six months ended June 30, 2025, ...

Announced on August 8, 2025, that the U.S. Food and Drug Administration (FDA) has approved the Genio® system for a subset of adult patients with moderate to severe OSA with an Apnea-Hypopnea Index ...

Idorsia Ltd (SIX: IDIA) announces the interim results of the repurchase offer for its outstanding CHF 204 * million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350) and CHF 600 million ...